創(chuàng)新藥物臨床試驗(yàn)中臨床藥理學(xué)研究的一般考慮-資料下載頁
2025-08-05 03:51本頁面
【正文】 J. Gabrielsson, D. Weiner. Pharmacokinetic amp。 Pharmacodynamic Data Analysis: Concept and Applications [M]. 4th ed. Stockholm: Swedish Pharmaceutical Press, 2006.[17] FDA. Guidance for Industry: Bioanalytical Method Validation [S]. 2001, 2013.[18] ICH. E7: Studies in Support of Special Populations: Geriatrics [S]. 1993.[19] FDA. Guideline for the Study of Drugs Likely to be used in the Elderly [S]. 1989.[20] ICH. E11: Clinical Investigation of Medicinal Products in the Pediatric Population[S]. 2000.[21] FDA. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products [S]. 1998。 and Appendix B in [12].[22] FDA. Guidance for Industry: Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs [S]. 1993.[23] ICH. E5(R1): Ethnic Factors in the Acceptability of Foreign Clinical Data[S]. 1998.[24] FDA. Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials [S]. 2005.[25] FDA. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling [S]. 2010.[26] CFDA. 腎功能損害患者的藥代動(dòng)力學(xué)研究技術(shù)指導(dǎo)原則 [S]. 2012.[27] FDA. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling [S]. 2003.[28] CFDA. 肝功能損害患者的藥代動(dòng)力學(xué)研究技術(shù)指導(dǎo)原則 [S]. 2012.[29] FDA. Guidance for Industry:Pharmacokinetics in Pregnancy?Study Design, Data Analysis, and Impact on Dosing and Labeling[S]. 2004.[30] FDA. Guidance for Industry: Clinical Lactation Studies?Study Design, Data Analysis, and Remendations for Labeling [S]. 2005.備注
外語相關(guān)推薦
鄂ICP備17016276號(hào)-1